IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study

Trial StartPositive

AI Analysis

Summary

Ionis Pharmaceuticals has completed enrollment in the pivotal cohort of its Angelman Syndrome study, representing progress toward potential regulatory advancement of its investigational therapy.

Clinical Trial Data

Outcome Details

Completed enrollment in pivotal cohort

Importance:6/10

Sentiment:

0.60

clinical trialAngelman Syndromeenrollmentrare disease

Related Companies

$IONS

Read the original article

Published by yahoo_finance on July 7, 2026 4:28 PM

Read Original